Servaas Michielssens joined Ackermans & van Haaren as Investment Manager in 2022 to reinforce the life science team and with the ambition to team up with European life science companies and support them in their journey to become global leaders. He started his career in 2007 as a researcher at the University of Leuven, following the completion of his PhD he moved to the Max Planck Institute in Göttingen, Germany. During his career as a researcher he developed algorithms and tools for computational drug design. In 2016 he joined Candriam as a senior biotechnology analyst, within Candriam he moved to the role of senior fund manager for the Biotechnology and Oncology strategy. Those strategies were investing in listed companies and had together $4B assets under management in 2022 when he moved to Ackermans & van Haaren.
